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Abstract
Background: Obstructive jaundice in patients with hilar cholangiocarcinoma is a known risk factor for
hepatic failure after liver resection. Plastic stents are most widely used for preoperative drainage.
However, plastic stents are known to have limited patency time and therefore, in palliative settings, the
self-expanding metal stent (SEMS) is used. This type of stent has been shown to be superior because it
allows for rapid biliary decompression and a reduced complication rate after insertion. This study explores
the use of the SEMS for biliary decompression in patients with operable hilar cholangiocarcinoma.
Methods: A retrospective evaluation of a prospectively maintained database at a tertiary hepatobiliary
referral centre was carried out. All patients with resectable cholangiocarcinoma were recorded.
Results: Of 260 patients referred to this unit with cholangiocarcinoma between January 2008 and April
2012, 50 patients presented with operable cholangiocarcinoma and 27 of these had obstructive jaundice
requiring stenting. Ten patients were initially treated with SEMSs; no stent failure occurred in these
patients. Seventeen patients initially received plastic stents, seven of which failed in the interval between
stent placement and laparotomy. These stents were replaced by SEMSs in four patients and by plastic
stents in three patients. Median time to laparotomy was 45 days and 68 days in patients with SEMSs and
plastic stents, respectively.
Conclusions: Self-expanding metal stents provide adequate and rapid biliary drainage in patients with
obstruction caused by hilar cholangiocarcinoma. No re-interventions were required. This probably reflects
the relatively short interval between stent placement and laparotomy.
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Introduction
Although cholangiocarcinoma is a relatively rare tumour type, its
incidence is rising worldwide.1 Because there are no early symp-
toms in this disease, patients often present at an advanced stage of
disease, which makes their prognosis extremely poor: 5-year sur-
vival rates are reported to be <10%.2 For both intrahepatic and
hilar tumours, resection is the only curative option, but fewer than
20% of patients are eligible for surgery after staging, usually
because of advanced disease. Patients diagnosed with a hilar
cholangiocarcinoma that is deemed to be operable often present
with obstructive jaundice, which is an established risk factor in
liver surgery.3–5 Surgery for hilar cholangiocarcinoma usually
involves an extended parenchymal resection, in which liver failure
is the most serious complication. It is therefore recommended that
preoperative biliary drainage (PBD) is performed in selected
patients with jaundice to reduce the risk for postoperative liver
failure.6,7
There has been much debate about the optimal technique
for PBD. Whereas some authors advocate the percutaneous
approach,8 endoscopic biliary drainage is the most commonly
used technique.9 In this approach, a plastic stent is usually inserted
to achieve biliary drainage. Plastic stents are relatively cheap and
are thought to cause less tissue reaction than metal stents.
However, plastic stents have a greater tendency to occlude and
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complications as a result of this occlusion are common.10 In the
palliative setting, the median patency time of plastic stents has
been identified as only 1.86 months.11 This is a major problem in
potentially resectable patients because the time from stenting to
explorative laparotomy is usually much longer and was found to
exceed 3 months in a recent study.8 For this reason, there is an
urgent need for a biliary decompression technique that provides
rapid relief of jaundice and has a low complication rate. In the
palliative setting, the self-expanding metal stent (SEMS) has been
proven superior to the plastic stent in terms of patency.11 This
study explores the use of SEMSs for biliary decompression in
patients with resectable hilar cholangiocarcinoma.
Materials and methods
Patients
From January 2008 to April 2012, 260 patients with a suspected
cholangiocarcinoma were referred to this hospital’s hepatobiliary
specialist multidisciplinary team meeting. The standard assess-
ment includes multi-slice triple-phase contrast computed tomog-
raphy (CT) scanning. When an intrahepatic cholangiocarcinoma
is suspected, magnetic resonance imaging (MRI) is performed to
further characterize the lesion. In the event of a suspected hilar
cholangiocarcinoma, endoscopic retrograde cholangiopancreati-
cography (ERCP) is used to specify the anatomic location of the
tumour and to grade it according to the Bismuth classification
scheme.12 Moreover, through ERCP a tissue diagnosis of the lesion
can often be obtained. In this unit, single-operator cholangios-
copy is used in selected cases to obtain detailed information of the
distal extent of the lesion and to obtain targeted biopsies. In the
jaundiced and malnourished patient, when the future liver
remnant is obstructed, a stent is placed across the lesion for biliary
decompression. If imaging has confirmed the suspicion of a
cholangiocarcinoma confined to the intrahepatic and/or extrahe-
patic bile ducts, and sufficient decompression of the bile ducts is
achieved, the patient then undergoes a formal anaesthetic assess-
ment including cardiopulmonary exercise testing. If the patient is
deemed fit for surgery, a staging laparoscopy is performed.13 If
no extrahepatic disease is found, the patient is scheduled for
laparotomy with a view to resection. The present study focuses on
patients who came to explorative laparotomy in the period from
January 2008 to April 2012.
Stent technique
All patients were given prophylactic antibiotics to limit the risk for
infection associated with hilar disease according to this unit’s local
policy. An ERCP procedure involving common bile duct cannu-
lation followed by selective wire-guided cannulation with a 0.035-
inch hydrophilic wire was performed in the future remnant
sector(s) of the liver.
When a satisfactory wire position had been achieved, a limited
cholangiogram was obtained both proximally and distally to the
stricture to enable cholangiographic staging of the tumour, par-
ticularly of its proximal extent, supplementing the pre-procedural
Bismuth classification obtained by cross-sectional imaging.12
Stenting was performed using either a 10-Fr plastic stent (Cook
Medical, Inc., Bloomington, IN, USA) or a Boston Wallflex uncov-
ered metallic stent with a 10-mm diameter (Boston Scientific
Corp., Natick, MA, USA). Metal stents were sited to ensure stric-
tures were crossed with a short intrahepatic segment upstream of
the tumour in order not to impede future resection planes
(Fig. 1). Care was taken to avoid unnecessary opacification of
sectors that did not require drainage. In all cases, the stents tra-
versed the ampulla, as per the standard approach in this unit.
Adequate stent positioning was confirmed by X-ray.
Definitions of events
The stenting procedure was considered technically successful
when the stent was placed across the stricture and initial biliary
Figure 1 Positioning of a self-expanding metal stent
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decompression was obtained. Stent failure was defined as the need
for a second intervention to obtain adequate biliary drainage. This
might be caused by an insufficient fall in bilirubin levels after the
initial procedure or might arise in the context of cholangitis or
cholecystitis. A patient was considered fit for laparotomy when
hyperbilirubinaemia was largely resolved and the patient’s nutri-
tional status was determined to be adequate by a dietician.
Results
During the period under study, 50 patients with suspected cholan-
giocarcinoma who qualified for explorative laparotomy were
identified (Fig. 2). Thirty-five patients had a hilar tumour. Eight
patients did not require any preoperative procedure because the
future liver remnant was not obstructed and the patients were
anabolic. A total of 27 patients presented with a hilar cholangi-
ocarcinoma causing obstructive jaundice. All of these patients
underwent stent placement, either at the referring hospital or at
the present unit. All procedures were technically successful. A total
of 17 patients were given plastic stents initially, but stent failure
occurred in seven of these patients at a median of 27 days (range:
10–50 days) after the first stent insertion. In three of these
patients, the plastic stent was replaced by a second plastic stent
(with subsequent failure in one patient, in whom a third plastic
stent was inserted 86 days and 55 days after placement of the first
and second stents, respectively). The remaining four patients in
whom plastic stents failed each received an SEMS replacement
stent.
In 10 patients, an SEMS was placed as the initial method of
biliary decompression; all of these placements were made at the
study unit. At this unit, SEMSs were used from 2010 and the
criteria for stenting did not differ between plastic stents and
SEMSs. As a result, the present sample included 14 patients with
SEMSs and 13 patients with plastic stents at the time of
laparotomy. In three patients, stents were inserted using a percu-
taneous approach (one metal and two plastic stents). The median
time between the first stent insertion and laparotomy was 68 days
(range: 6–114 days) in patients in whom initial stents were plastic
and 45 days (range: 35–69 days) in patients who initially received
SEMSs. There were no cases of post-ERCP pancreatitis.
At explorative laparotomy, eight of the 27 stented patients (four
with plastic and four with metal stents) were deemed to be inop-
erable as a result of peritoneal seeding (n = 7) or tumour growth
into the duodenum (n = 1); all of these diagnoses were biopsy-
proven. In all the resected patients, frozen-section biopsies
obtained from the proximal and distal resection margins of the
bile duct indicated margins were tumour-free. However, final
paraffin-embedded histology of the distal resection margin in one
patient, in whom a metal stent had been placed, indicated tumour
cells (R1 resection). Final histology in two other patients, of whom
one belonged to the plastic stent group and the other to the SEMS
group, showed an R1 resection as the intrahepatic portion of the
tumour reached the parenchymal resection plane. In one further
patient, final histology showed immunoglobulin 4-related sclero-
sing disease. The extents and final outcomes of resections are
shown in Table 1.
Discussion
This study, although it is subject to the potential bias inherent to
retrospective studies, shows that the use of SEMSs in operable
patients with hilar cholangiocarcinoma is feasible. The wider
lumens of the SEMS provide for rapid biliary decompression,
making proximal sepsis, which is caused by inadequate antegrade
biliary flow, much less likely. In this series, no re-interventions
were necessary. Rapid decompression enables the patient to
recover quickly and therefore the interval between biliary decom-
pression and explorative laparotomy can be relatively short.
The median time to laparotomy of 45 days following the inser-
tion of an SEMS in this study compares favourably with data in
the literature. Many studies on preoperative stenting fail to report
the median time interval between stenting and laparotomy, but
one recent study cited a median time to laparotomy of 15 weeks.8
This probably reflects the patient selection strategy used: only
patients of inadequate nutritional status caused by obstructive
jaundice, and patients in whom the future liver remnant was
obstructed were considered for preoperative drainage. When the
enterohepatic cycle is restored, nutritional status improves and a
patient will be considered for surgery once he or she becomes
anabolic. Moreover, hepatic regeneration is impaired in the jaun-
diced patient and the full restoration of hepatic function and
260 patients referred 
to SMDT 
50 patients had
explorative laparotomy 
15 patients had
intrahepatic
cholangiocarcinoma 
35 patients had hilar
cholangiocarcinoma 
8 patients had no
obstructive jaundice 
27 patients had
obstructive jaundice 
17 patients had 
initial plastic stents
10 patients had
initial SEMSs
Stents failed
in 7 patients
Plastic stents inserted
in 3 patients
SEMSs inserted
in 4 patients
Figure 2 Flow chart of patients. SMDT, specialist multidisciplinary
team; SEMS, self-expanding metal stent. The patient with immu-
noglobulin 4-related sclerosing disease is included
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regeneration capacity takes 4–6 weeks after biliary decompres-
sion.14 Therefore, when major hepatic resection is planned
(particularly resections requiring preoperative portal vein emboli-
zation), stenting is often required and the interval between stent-
ing and laparotomy is usually prolonged.
The present study was not designed to establish the role of
SEMS use in the preoperative setting. The small number of
patients, the retrospective setting and the absence of strict and
uniform criteria for the insertion of stents and for establishing the
optimal timing of the operation according to bilirubin level and
nutritional status are all significant shortcomings of the present
study. However, this study shows important possible benefits of
SEMS use and therefore a prospective comparative study to define
the possible role of the SEMS in operable cholangiocarcinoma is
proposed.
It is of fundamental importance that the insertion of an SEMS
in a patient with potentially operable hilar cholangiocarcinoma
takes place in the tertiary setting. Stent placement, especially when
metal stents are used, requires the close collaboration of the inter-
ventional endoscopist and the hepatobiliary surgeon. Full cross-
sectional imaging should be obtained prior to the intervention,
which should then be undertaken with a clear plan and objectives.
Injudicious intervention or SEMS placement will dramatically
compromise the management of the patient by opacifying
Table 1 Stents and outcomes in 27 patients with hilar cholangiocarcinoma who underwent laparotomy with a stent in situ
Patient Bismuth
grade
Initial stent Second
stent
Interval
between
stents, days
Operation Interval to
laparotomy,
days
Outcome
1 IIIb Plastic L hemi + caudate + CBD + hep-jej 95 IgG-4
2 IIIa Plastic Plastic 50 R hemi + CBD + hep-jej 70 R1a
3 Plastic Open-and-close 114 N/A
4 GB cancer Plastic Plastic 10 GB + IV/V res + CBD 28 R0
5 IIIb Plastic L hemi + caudate + CBD + hep-jej 66 R0
6 IIIa Ptc – plastic int–ext R hemi + caudate + CBD + hep-jej 6 R0
7 Plastic Open-and-close 78 N/A
8 IIIb Metal L hemi + CBD + hep-jej 43 R0
9 IIIb Plastic L hemi + caudate + CBD + hep-jej 33 R0
10 IIIa Metal R tri + CBD + hep-jej 54 R1b
11 Metal Open-and-close 44 N/A
12 IIIb Plastic Ptc – metal 26 L hemi + CBD + hep-jej 101 R0
13 IV Plastic R tri + CBD + PV + hep-jej 24 R0
14 Metal Open-and-close 35 N/A
15 Plastic Metal 10 Open-and-close 88 N/A
16 IIIa Plastic Metal 27 R tri + CBD + hep-jej 61 R0
17 Metal Open-and-close 69 N/A
18 Plastic Plastic 31c Open-and-close 93 N/A
19 II Plastic R tri + CBD + PV + hep-jej 104 R0
20 Plastic Open-and-close 50 N/A
21 I Plastic Metal 33 CBD + part PV + hep-jej 59 R0
22 IIIb Metal L hemi + caudate + CBD + hep-jej 55 R0
23 II Metal CBD + hep-jej 63 R0
24 IV Metal R tri + caudate + CBD + PV + hep-jej 37 R1a
25 IIIb Metal L hemi + caudate + CBD + hep-jej 45 R0
26 IV Ptc – plastic int–ext R tri + caudate + CBD + PV + hep-jej 50 R0
27 IIIb Metal L hemi + caudate + CBD + hep-jej 53 R0
aR1 resection based on the intrahepatic portion of the tumour reaching the parenchymal resection plane.
bR1 resection based on the distal resection margin of the bile duct containing tumour cells on final paraffin-embedded histology; frozen-section
analysis was negative.
cThis patient experienced a second failure at 86 days after the first (and 55 days after the second) stent and had a third plastic stent inserted.
GB, gallbladder; Ptc, percutaneous transhepatic cholangiography; int–ext, internal–external; L hemi, left hemihepatectomy; R hemi, right hemihepa-
tectomy; IV/V res, segments IV/V resection; CBD, common bile duct; hep-jej, hepaticojejunostomy; PV, portal vein; R tri, right trisectionectomy; IgG4,
immunoglobulin 4-related sclerosing disease; R0, microscopically margin-negative resection; R1, microscopic margin positive for tumour; N/A, not
applicable.
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undrained segments and increasing the attendant risk for sepsis,
compromising the further acquisition of tissue if required or ren-
dering resection impossible by excessively proximal stent place-
ment. Health service networks should facilitate the prompt
referral of patients with malignant proximal biliary obstruction to
enable the early involvement of tertiary specialists in their care.
Many studies conducted in the palliative setting have compared
outcomes of the use of plastic and metal stents, respectively. In
general, metal stents are superior in terms of patency and are
therefore recommended.15,16 In a recent comparative assessment,
the median patency of plastic stents was found to be 1.86 months,
which is significantly shorter than the patency of 5.56 months
identified for metal stents.11 This means that the median patency
of plastic stents (in the palliative setting) is shorter than the
time between stenting and laparotomy (in preoperatively stented
patients). Thus, during the interval between stenting and
laparotomy, at least 50% of patients with plastic stents can be
expected to require some form of re-intervention. A recent study
found that a mean of 2.8 preoperative drainage procedures were
required in patients in whom endoscopic plastic stents were used.8
The majority of these re-interventions were for infectious com-
plications, which occurred in 48% of patients.8 This high rate of
infectious complications is comparable with rates reported
elsewhere in the literature17,18 and therefore it is likely that
re-intervention rates will be relatively high across the world.
The precise role of preoperative stenting is still subject to dis-
cussion.19 A Cochrane review published in 200820 concluded that
preoperative drainage could be neither supported nor refuted
because the trials included in the meta-analysis were of insuffi-
cient quality. Moreover, most trials investigating preoperative
biliary drainage have focused mainly on distal obstructions that
do not necessitate liver parenchymal resection.21–24 Although
biliary stenting is not recommended as a standard preoperative
procedure,25,26 it is recommended in patients with significant
biliary obstruction because persistent jaundice is a risk factor for
postoperative liver failure.6,7 Patients in a catabolic state will
benefit from preoperative drainage when the enterohepatic cycle
is restored.27
The preferred method of biliary drainage is also controversial.
Some authors advocate the percutaneous approach because it is
presumed to carry a lower risk for infectious complications and to
enable the targeting of specific sectors for drainage, although
improvements in ERCP technique now frequently enable sector-
specific drainage at ERCP.8 Others argue that the endoscopic
approach is less invasive and enables enteral drainage and hence
presumed better nutritional status.27 Endoscopic drainage can be
performed by endoscopic stenting or endoscopic nasobiliary
drainage, the second of which is presumed to be associated with
reduced risk for infectious complications.6,28,29 What is clear is that
poorly performed attempts at drainage by either route are worse
than no drainage at all.
The preoperative use of metal stents is limited by the fact that
intraoperative assessment of the extent of the tumour may be
more difficult as the fibrotic reaction is likely to be more pro-
nounced if an SEMS is used than if a plastic stent is inserted. This
is believed to lead to technical difficulties during resection and to
a higher complication rate.30,31 Self-expanding metal stents have
recently been used in distal cholangiocarcinoma, which is subject
to the same concerns about technical difficulties, but no stent-
related complications occurred either intra- or postoperatively.32
In the present study, no technical difficulties in intraoperative
assessment were encountered and the resection planes chosen
were all found to be free of tumour on frozen-section analysis.
Neither were there any major difficulties in removing the stent
from the distal bile duct before its closure. Another possible
concern refers to the pathological assessment of the specimen
with an SEMS in situ. Again, in the present study this did not
appear to be a problem and adequate assessment of the epithelium
of the bile ducts was possible in all cases.
Metal stents are considerably more costly than plastic stents.
However, the possible costs of further interventions may consid-
erably outweigh the primary stent costs, depending on the
number of re-interventions required.33 In the palliative setting,
Moss et al.34 performed a meta-analysis of randomized controlled
trials comparing the use of plastic and metal stents for obstruc-
tions in both proximal and distal biliary tumours. The use of
SEMSs was found to be cost-effective when additional procedures
carried out in association with the use of plastic stents cost more
than US$1820.34 In distal biliary obstructions, initial placement of
an SEMS was found to cause a 28% decrease in further endoscopic
procedures in a prospective randomized trial.35 The literature does
not include any data on the issue of cost-effectiveness in the
context of proximal obstructions in a preoperative setting and
the present study was not designed to make a cost-effectiveness
analysis.
Recently, a study from the MD Anderson Cancer Center showed
that preoperative metal stenting in patients with a malignant
distal biliary obstruction is feasible.32 The use of neoadjuvant
strategies in these patients is gaining in popularity and therefore
many patients will require biliary decompression because the time
between diagnosis and surgery will be prolonged.36 For proximal
biliary tumours, neoadjuvant therapies are not considered to rep-
resent a standard of care. However, a recent study by Gruenberger
et al.37 has shown promising results of induction chemotherapy
using cetuximab, gemcitabine and oxaliplatin. Of the 30 primarily
unresectable patients in this study, nine patients underwent inten-
tional curative resection after induction chemotherapy.37 The
introduction of neoadjuvant strategies in hilar cholangiocarci-
noma will increase interest in biliary stents that provide superior
longlasting biliary decompression.
Conclusions
The present study shows that SEMSs provide adequate biliary
drainage and do not preclude subsequent curative surgery
in selected patients in whom obstruction is caused by hilar
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cholangiocarcinoma. The reduced need for re-interventions in
patients in whom SEMSs have been inserted is promising, but the
possible superiority of the SEMS can only be proven in a prospec-
tive setting.
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